Gastric cancer is one of the most common cancers in the world,and with the rise of immune-targeted therapy,it has provided new treatment options for many patients with advanced gastric cancer.However,not all cancer patients can benefit from monoclonal antibody therapy against programmed death-1 and its ligand and against cytotoxic T lymphocyte associated antigen-4.Therefore,the discovery of new immune checkpoints has become a future therapeutic trend.In this review,we summarized and analyzed the biological characteristics of V-domain Ig suppressor of T cell activation,B7 homolog 3 and lymphocyte-activation gene 3 of novel immune checkpoint T cell activation,as well as their effects on the occurrence and development of gastric cancer.At the same time,the effectiveness of corresponding immunosuppressants in preclinical and clinical trials was also evaluated,in order to provide a theoretical reference for the targeted therapy of gastric cancer.

Hepatocellular carcinoma （HCC） is the most common type of primary liver cancer and the third leading cause of cancer-related deaths， and it is a serious threat to human health and has become a clinical problem that needs to be solved urgently. Extracellular vesicles （EV） are membrane vesicles containing multiple components and play an important role in the development and progression of HCC. This article summarizes the effect of EVs of different origins on HCC and analyzes the mechanism of action of EV on HCC， so as to provide new perspectives for the diagnosis and treatment of HCC.

Objective To explore the independent risk factors that affect the overall survival (OS) of elderly patients with hepatocellular carcinoma (HCC, ≥60 years old) and build a nomogram prediction model. Methods Clinical data of all elderly patients with HCC from the SEER database from 2005 to 2020 were downloaded from SEER database. In accordance with the inclusion and exclusion criteria, the screened patients were randomly assigned to a training group (70%) and a validation group (30%). The independent risk factors of elderly patients with HCC were determined by univariate and multivariate Cox regression analyses and further validated by Kaplan-Meier survival analysis. On the basis of the determined variables, nomograms were developed and verified to predict the OS of elderly patients with HCC at 6, 12, and 24 months. The consistency index (C index), calibration curve, receiver’s operating characteristic (ROC) curve, and area under curve (AUC) were used to evaluate the prediction efficiency and discrimination ability of the prediction model, and decision curve analysis (DCA) was used to evaluate the potential clinical application value of the nomogram. Results A total of 1134 elderly patients with HCC were included, with 793 in the training group and 341 in the validation group. Seven variables, including age, clinical grade, clinical stage, M stage, tumor size classification, and radiotherapy, were identified as independent prognostic factors of this population. The constructed nomogram shows excellent prediction performance, with C indices of 0.745 in the training group and 0.704 in the validation group. The AUC values of the training group at 6, 12, and 24 months were 0.785, 0.788, and 0.798, respectively, and those of the validation group were 0.780, 0.725, and 0.607, respectively. The calibration curve shows good consistency from the predicted survival probability to the actual probability. The ROC curve and DCA show that the nomogram proposed in this study has good prediction ability. Conclusion Age, clinical grade, clinical stage, M stage, tumor size classification, and radiotherapy are important influencing factors for the survival of elderly patients with HCC. The prediction model of prognosis nomogram constructed in this study has good predictive value, and it can be used to predict the OS of elderly patients with HCC, which could be helpful for individualized survival assessment and clinical management of these patients.